Physician profile
Jonathan Winkler
NPI 1528470267
$9,536.98
in general payments reported to CMS, 2019-2025
40 companies · $2,599 in 2025
The $2,599 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2021: $160 · 2022: $1,326 · 2023: $2,316 · 2024: $2,994 · 2025: $2,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,908.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $872.73 | 2022-2025 | |
| Pfizer INC. | $777.91 | 2022-2025 | |
| Novo Nordisk INC | $705.50 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $673.21 | 2022-2025 | Jardiance |
| Abbott Laboratories | $672.68 | 2019-2025 | Jot Dx, Cardiomems |
| Amgen INC. | $633.07 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $628.22 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $493.15 | 2022-2025 | Watchman Flx, Watchman Access System, Watchman |
| E.R. Squibb & Sons, L.L.C. | $462.57 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $461.16 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $407.68 | 2021-2025 | Farxiga, Wainua |
| Esperion Therapeutics, INC. | $316.03 | 2021-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $307.75 | 2022-2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $227.07 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Bridgebio Pharma, INC. | $179.98 | 2025 | Attruby |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $179.68 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $128.15 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $128.12 | 2023-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $123.93 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $120.78 | 2024-2025 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $107.51 | 2023-2024 | Inpefa |
| Abiomed | $105.20 | 2024-2025 | Impella |
| Heartflow, INC. | $96.05 | 2023-2025 | Ffrct |
| Impulse Dynamics (USA) INC. | $88.77 | 2022-2024 | Optimizer, Optimizer |
| Daiichi Sankyo INC. | $85.02 | 2023 | Injectafer |
| Medtronic, INC. | $83.19 | 2025 | Symplicity G3 |
| Atricure, INC. | $69.83 | 2024-2025 | Atriclip Laa Exclusion System, Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax |
| Medicomp INC | $45.30 | 2024 | Telepatch Cardiac Monitor |
| Lilly USA, LLC | $40.23 | 2025 | Mounjaro, Zepbound |
| Philips North America LLC | $37.84 | 2022 | |
| Amarin Pharma, INC. | $35.68 | 2022-2023 | |
| Scpharmaceuticals INC. | $35.65 | 2023 | |
| Chiesi USA, INC. | $33.93 | 2024 | Juxtapid |
| Bracco Diagnostics INC. | $33.75 | 2025 | |
| Corcept Therapeutics | $31.20 | 2021 | |
| Cvrx, INC. | $28.24 | 2023 | Barostim Neo System |
| Glaxosmithkline, LLC. | $25.91 | 2025 | Shingrix |
| Amryt Pharma Holdings Ltd | $20.92 | 2023 | Juxtapid |
| Kiniksa Pharmaceuticals, Ltd. | $18.52 | 2023 | Arcalyst |
| Siemens Medical Solutions USA, INC. | $14.87 | 2023 | Acuson Sequoia Diagnostic Ultrasound System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Winkler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.